文献速递贫血与红细胞疾病

育龄期女性缺铁筛查铁蛋白阈值的成本效益分析

Cost-Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive-Age Women.
PubMed 文献 · Am J Hematol · 2025-04-16

本研究采用马尔可夫队列模型模拟美国育龄期女性终生结局,比较不筛查、铁蛋白阈值15 μg/L筛查和25 μg/L筛查三种策略。25 μg/L筛查最具成本效益,ICER为每QALY 680美元(95%可信区间350-750),在静脉补铁情景下仍具成本效益(ICER每QALY 2300美元)。

要点

  • 美国育龄期女性缺铁筛查与不筛查相比,铁蛋白阈值25 μg/L筛查具成本效益。
  • 25 μg/L筛查的ICER为每QALY 680美元(95%可信区间350-750)。
  • 静脉补铁情景下25 μg/L筛查仍具成本效益,ICER为每QALY 2300美元(95%CI 1800-3800)。

核心结论

  • 在美国育龄期女性中,铁蛋白阈值25 μg/L筛查是具成本效益的干预策略,ICER为每QALY 680美元(95%可信区间350-750)。

研究设计与样本

  • 采用马尔可夫队列模型对美国育龄期女性进行终生模拟,从美国卫生系统视角比较不筛查、铁蛋白阈值15 μg/L筛查和25 μg/L筛查三种策略,支付意愿阈值为每QALY 100 000美元。
  • 模型参数采用基于国家健康与营养调查(NHANES)的缺铁患病率估计。

主要发现

  • 三种策略的贴现终生成本分别为209 700美元、210 200美元和210 200美元,贴现终生QALY分别为23.6、24.0和24.4。
  • 铁蛋白阈值25 μg/L筛查的ICER为每QALY 680美元(95%可信区间350-750)。
  • 在静脉补铁替代口服补铁的双重基础案例分析中,25 μg/L筛查仍具成本效益,ICER为每QALY 2300美元(95%CI 1800-3800)。
  • 在概率敏感性分析中,25 μg/L筛查在10 000次二阶蒙特卡洛迭代中100%具成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron deficiency (ID) is a top five leading cause of disability-adjusted life-years in women of reproductive age around the world. Despite its enormous health burden, no screening guidelines exist for the detection and treatment of ID in women of reproductive age. We sought to determine the cost-effectiveness of screening versus no screening for ID in women of reproductive age in the United States. A lifetime simulation of women of reproductive age was conducted using a Markov cohort model under three strategies: (1) no screening, (2) screening at a ferritin threshold of 15 μg/L, and (3) screening at a ferritin threshold of 25 μg/L, from the US health system perspective, and at a willingness-to-pay threshold of $100 000/quality-adjusted life year (QALY). Epidemiologically informed ID prevalence estimates sourced from the National Health and Nutrition Examination Survey were employed for model parameterization. The primary outcome was the incremental cost-effectiveness ratio (ICER, in $/QALY). Base-case results for the three strategies accrued $209 700, $210 200, and $210 200 discounted lifetime costs and 23.6, 24.0, and 24.4 discounted lifetime QALYs, respectively. Screening at a ferritin threshold of 25 μg/L was the cost-effective intervention with an ICER of $680/QALY (95% credible interval $350-$750/QALY). In dual base-case analyses examining intravenous rather than oral iron repletion for treatment, screening at a ferritin threshold of 25 μg/L remained the cost-effective intervention with an ICER of $2300/QALY (95% CI $1800-$3800/QALY). In probabilistic sensitivity analyses, screening at a ferritin threshold of 25 μg/L was the cost-effective intervention in 100% of 10 000 second order Monte Carlo iterations.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Wang D, Sra M, Glaeser-Khan S, et al. Cost-Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive-Age Women. Am J Hematol. 2025. PMID: 40235279. doi:10.1002/ajh.27686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。